{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011235","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.191807+00:00","generated_at":"2026-06-04T08:16:21.902364+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enveric Biosciences reports Q4 2023 net loss of $3.44M; selects EB-003, signs out-licensing term sheets","bullets":["Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.","Selected EB-003 as lead neuroplastogen candidate for depression/anxiety without hallucinations.","Signed non-binding term sheets to out-license three compound classes (up to $200M milestones) and cannabinoid conjugates (up to $61M).","Completed warrant inducement exercises raising ~$4.5M gross proceeds.","Advanced IND-enabling studies for EB-002 including toxicology and safety pharmacology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011235","json":"https://secwatch.observer/filing/0001493152-24-011235.json","markdown":"https://secwatch.observer/filing/0001493152-24-011235.md","text":"https://secwatch.observer/filing/0001493152-24-011235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224011235/0001493152-24-011235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224011235/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:16:21.902364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3dae5df7c368166f1d23c768c4ce88ad6bb23822","claim":"Enveric Biosciences, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: net income $3.44 million for the fourth quarter ended December 31, 2023, EPS $1.46.","evidence_excerpt":"Net loss attributable to stockholders was $3.44 million for the fourth quarter ended December 31, 2023, including $1.48 million in net non-cash expense, with a basic and diluted loss per share of $1.46, as compared to a net loss of $8.80 million, including $4.48 million in net non-cash expense, with a basic and diluted loss per share of $4.89 for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315224011235/0001493152-24-011235-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2023"},{"label":"Net income","value":"$3.44 million for the fourth quarter ended December 31, 2023"},{"label":"EPS","value":"$1.46"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}